Translational success of fundamental virology: a VSV-vectored Ebola vaccine

Ebola virus disease (EVD) caused by Ebola virus (EBOV) is a severe, often fatal, hemorrhagic disease. A critical component of the public health response to curb EVD epidemics is the use of a replication-competent, recombinant vesicular stomatitis virus (rVSV)-vectored Ebola vaccine, rVSVΔG-ZEBOV-GP...

Full description

Saved in:
Bibliographic Details
Published in:Journal of virology 2024-03, Vol.98 (3), p.e0162723
Main Authors: Anderson, Elizabeth M, Coller, Beth-Ann G
Format: Article
Language:English
Subjects:
Ebola Vaccines - genetics
Ebola Vaccines - immunology
Ebolavirus - genetics
Ebolavirus - immunology
Gem
Genetic Vectors - genetics
Hemorrhagic Fever, Ebola - immunology
Hemorrhagic Fever, Ebola - prevention & control
Humans
Public-Private Sector Partnerships
Vaccines
Vesiculovirus - genetics
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ebola virus disease (EVD) caused by Ebola virus (EBOV) is a severe, often fatal, hemorrhagic disease. A critical component of the public health response to curb EVD epidemics is the use of a replication-competent, recombinant vesicular stomatitis virus (rVSV)-vectored Ebola vaccine, rVSVΔG-ZEBOV-GP (ERVEBO). In this Gem, we will discuss the past and ongoing development of rVSVΔG-ZEBOV-GP, highlighting the importance of basic science and the strength of public-private partnerships to translate fundamental virology into a licensed VSV-vectored Ebola vaccine.
ISSN:0022-538X
1098-5514
1098-5514
DOI:10.1128/jvi.01627-23